Walmart expands opioid stewardship efforts, limits acute prescriptions to seven days

A customer drops off a prescription for short-term pain relief, and the Walmart pharmacist has to do more than count pills. Under the company’s opioid stewardship approach, an initial acute prescription can be capped at seven days and, in Walmart’s 2018 policy, at no more than 50 morphine milligram equivalents per day, turning the pharmacy counter into the front line of a public-health decision.

Walmart and Sam’s Club say they were the first national pharmacy chains to limit initial opioid prescriptions for acute conditions to seven days. Walmart said in May 2018 that the change would be in place within 60 days, and it also said controlled substances would require e-prescriptions by Jan. 1, 2020. The company says the shorter supply is meant to cut down on excess pills that can be vulnerable to diversion. For pharmacy teams, that means the script on the screen is only the start of the interaction. Patients may ask why they are getting fewer tablets than expected, and pharmacists are left to explain the limit while still using judgment within the bounds of prescribing guidance.

Walmart ties that policy to a broader controlled substance stewardship effort. The company says the opioid epidemic continues to take a devastating toll and cites FDA data showing more than 6 million people in the United States have an opioid use disorder. Its stewardship page also says Walmart helps people dispose of unused drugs, funds prevention education in schools, stocks overdose medication where allowed by law, and supports law enforcement and relevant legislation. Walmart says it has worked with the DEA’s 360 Strategy initiative, regional DEA offices, the Mark Wahlberg Youth Foundation, Operation Engage and the Gavin Foundation on National Youth Summits for middle and high school students. The DEA’s 360 Strategy is built around law enforcement, diversion control and community outreach.

The policy sits inside a larger legal and financial reckoning. In November 2022, Walmart announced a $3.1 billion nationwide opioid settlement framework to resolve substantially all opioid lawsuits and potential lawsuits brought by state, local and tribal governments. By December 2022, Walmart said it had reached settlement agreements with all 50 states, the District of Columbia, Puerto Rico and three U.S. territories. Massachusetts said its share would be more than $61 million, Colorado said it would receive more than $40 million, and New York said the deal could provide up to $116 million.

For hourly associates, department managers and pharmacy leaders, the message is clear: opioid policy is not abstract corporate messaging. It shapes what happens at the counter, how a pharmacist answers a patient’s questions, and how Walmart wants its stores to be seen in communities still living with the cost of the crisis.